The Absence of LPA2 Attenuates Tumor Formation in an Experimental Model of Colitis-Associated Cancer

Songbai Lin, Emory University
Dongsheng Wang, Emory University
Amr M. Ghaleb, Emory University
Hyunsuk Shim, Emory University
Vincent W. Yang, Emory University
Jerold Chun, Scripps Research Institute
Chris Yun, Emory University
Smita Iyer, Emory University

Journal Title: Gastroenterologie
Volume: Volume 136, Number 5
Publisher: Springer Verlag (Germany) | 2009-05, Pages 1711-1720
Type of Work: Article | Post-print: After Peer Review
Publisher DOI: 10.1053/j.gastro.2009.01.002
Permanent URL: http://pid.emory.edu/ark:/25593/bskc6

Final published version: http://dx.doi.org/10.1053/j.gastro.2009.01.002

Copyright information:
© 2009 by the AGA Institute
This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Accessed December 2, 2019 10:02 AM EST
The absence of LPA2 attenuates tumor formation in an experimental model of colitis-associated cancer

Songbai Lin1, Dongsheng Wang1, Smita Iyer2, Amr M. Ghaleb1, Hyunsuk Shim3,4, Vincent W. Yang1,4, Jerold Chun6, and C. Chris Yun1,2,5

1 Division of Digestive Diseases, Department of Medicine, Emory University School of Medicine, Atlanta
2 Nutrition and Health Sciences Program, Emory University School of Medicine, Atlanta
3 Department of Radiology, Emory University School of Medicine, Atlanta
4 Winship Cancer Institute, Emory University School of Medicine, Atlanta
5 Department of Physiology, Emory University School of Medicine, Atlanta
6 Department of Molecular Biology, Scripps Research Institute, La Jolla

Abstract

Background & Aims—Chronic inflammation is a risk factor for colon cancer (CC). Lysophosphatidic acid (LPA), a naturally produced phospholipid, mediates multiple effects that are vital to disease process, including inflammation and cancer. The expression of LPA receptor 2 (LPA2) is up-regulated in several types of cancer, including ovarian and colon cancer, but the importance of LPA and LPA2 in the development and progression of CC is unclear. In this study, we sought to determine whether LPA and LPA2 regulate the progression of CC in vivo.

Methods—We examined the potential role of LPA in CC progression by administering LPA to Apcmin/+ mice. We determined the loss of LPA2 function in tumorigenesis in the colon by treating mice with genetic deletion of LPA2 (LPA2−/−) with azoxymethane (AOM) and dextran sulfate sodium (DSS).

Results—We found that LPA increased tumor incidence in Apcmin/+ mice. LPA2−/− mice showed reduced mucosal damage and fewer tumors than wild-type (WT) mice. Reduced epithelial cell proliferation and decreases in β-catenin, Krüppel-like factor 5 (KLF5), and cyclooxygenase-2 (COX-2) expression were observed in LPA2−/− mice. Unlike WT mice, induction of monocyte chemoattractant protein-1 (MCP-1) and macrophage migration inhibitory factor (MIF) was significantly attenuated in LPA2−/− mice with reduced infiltration by macrophages.

Conclusion—These results show that LPA is capable of promoting tumorigenesis in the colon. The absence of LPA2 attenuates several effects that contribute to cancer progression in vivo and, hence, the current study identifies LPA2 as an important modulator of CC.
INTRODUCTION

CC is the fourth most common cancer and inflammation is an established risk factor for CC. Patients with inflammatory bowel disease are at increased risk for CC and the mortality in patients diagnosed with CC in the setting of IBD is higher than for sporadic colorectal cancer.

LPA is an extracellular lipid mediator that evokes multiple growth factor-like effects in almost every cell type. LPA mediates its effects primarily by coupling to a family of G protein-coupled receptors, LPA1–LPA5. The initial indication that LPA could contribute to tumorigenesis came from studies showing that LPA increases cell proliferation and motility. Subsequently, over-expression of LPA2 in ovarian cancer cells has suggested that aberrant LPA-LPA2 signaling axis might have a tumor promoting activity in ovarian cancer. Recent evidence shows that deregulation of LPA2 or LPA3 is more commonly found in other types of cancer.

Mice deficient in individual LPA receptors are available. Whereas mice with targeted deletion of LPA1 or LPA3 show receptor-specific defects such as craniofacial deformity or delayed implantation of embryos, genetic ablation of LPA2 in mice (LPA2−/−) does not cause any obvious phenotypic defect. Moreover, transgenic expression of LPA2 in ovaries did not result in ovarian malignancy in mice. Although the absence of tumors in LPA2 transgenic mice implies a non-essential or redundant role of LPA2 in tumorigenesis, a body of in vitro experimental evidence tends to suggest the insufficiency of LPA-LPA2 signaling axis to induce malignancy in ovary. Therefore, the significance of LPA2 in tumorigenesis remains unclear and specific pathways affected are not known.

AOM, a metabolite of 1,2-dimethylhydrazine, has been used widely to induce the formation of precancerous epithelial lesions, aberrant crypt foci (ACF). Together with AOM, repeated oral administration of DSS is widely employed to induce acute inflammatory reaction and ulceration in the entire colon, and accelerates and increases the incidence of colon carcinogenesis. The potential role of LPA in inflammation has extensively been studied and chronic inflammation increases the risk of CC. In this study we investigated the loss of LPA2 function in colitis-associated cancer (CAC). Our study revealed that the extent of colon carcinogenesis was markedly decreased in LPA2−/− mice with decreased epithelial cell proliferation and infiltration of inflammatory leukocytes.

METHODS

Mice

LPA2−/− mice were bred into C57BL/6 background for at least 10 generations. LPA2+/− mice were crossbred to derive WT (i.e., LPA2+/+), LPA2+/−, and LPA2−/− littermates and these littermates were used in all studies. Experiments with animals were carried out under approval by the Institutional Animal Care and Use Committee of Emory University.

LPA treatment

Six weeks old male C57BL/6 and ApcMin/+ mice (Jackson Laboratory) were given 1 μg/kg LPA suspended in 0.1% BSA containing PBS (~0.06 μmole per mouse; Avantis) by placing LPA into the stomach using a 22-gauge gavage needle once every three days for one month. Control animal received the same volume of PBS/0.1% BSA. Animals were killed one month after the last LPA administration. The small intestine was removed, flushed with ice-cold PBS, cut open longitudinally along the main axis, and examined under a dissecting microscope for the presence of adenomas.
AOM and DSS treatment
WT, LPA$_2^{+/−}$, and LPA$_2^{−/−}$ littermates of 6 to 8 week-old age were injected with 10 mg/kg of AOM (Midwest Research Institute) intraperitoneally at the beginning of the experiment. After 14 day, mice were given 3% DSS (Sigma-Aldrich) in drinking water for 7 days, followed by a 2 week-period of recovery with normal water. This was followed by another 1-week 3% DSS treatment and 2-weeks of normal water. Body weight of each mouse was measured and recorded daily. Mice were killed on day 36 or day 56. Colon was removed, flushed with ice-cold PBS, cut open longitudinally, and examined under a dissecting microscope for the presence of tumors as previously described. Colonic tissues were fixed in 10% buffered formalin overnight for histological analysis. Paraffin embedded sections were stained with hematoxylin and eosin (H&E) for microscopic assessment of colitis.

AOM treatment
LPA$_2^{−/−}$ and WT littermates of 5–6 weeks old age received 4 weekly intraperitoneal injections of AOM at 10 mg/kg body weight. Four weeks after the last AOM injection, all mice were killed, and their colons were removed and fixed in 4% paraformaldehyde. Fixed tissues were stained with methylene blue and ACF were visualized by stereo microscopy. ACF were identified using a published set of criteria.

Immunohistochemistry
See Supplementary Materials.

Myeloperoxidase Activity
See Supplementary Materials.

Quantitative RT-PCR (qRT-PCR)
See Supplementary Materials.

Statistic Analysis
Data are expressed as means ± SE. Statistical significance was determined by one-way ANOVA. p-values <0.05 were considered significant.

RESULTS
Effect of LPA on the development of adenomas in Apc$^{Min/+}$ mice
Previous studies have shown that LPA$_2$ expression is elevated in human CC patients and cell lines. qRT-PCR analysis showed that LPA$_2$ mRNA level was elevated 3.5 ± 0.78 fold (n = 6) in intestinal adenomas of Apc$^{Min/+}$ mice compared to normal intestinal tissue from WT controls (Figure 1A). There was a small statistically significant increase in LPA$_1$ in Apc$^{Min/+}$ mice (P < 0.05) as well, but LPA$_3$ expression was not different.

LPA plays a vital role in intestinal wound healing, cell proliferation, cell survival, cytokine induction, and regulation of ion transport. We initially tested whether LPA regulates tumorigenesis in the colon by orally administering LPA to Apc$^{Min/+}$ mice. Although the stability of orally administered LPA may be a concern, a previous study has shown that orally administered LPA is effective in inhibition of fluid secretion in the ileum, demonstrating the bioavailability of orally administered LPA in the intestine. Administration of LPA increased the number of adenomas (60 ± 5.2, n = 9, P < 0.001) in Apc$^{Min/+}$ mice compared to Apc$^{Min/+}$ mice that received carrier (32 ± 6.7, n = 9) (Figure 1B). This result shows that LPA...
may potentiate tumorigenesis in the colon, although whether this effect was mediated by LPA2 is unclear.

**Reduced tumor incidence in LPAβ−/− mice**

We next sought to determine the importance of LPA2 in colon tumorigenesis by characterizing the loss of LPA2 function in vivo. To this end, we used a CAC model, which combines the treatment of mice with AOM and DSS (Figure 2A). AOM and DSS induced colitis in WT, LPA2+/−, and LPA2−/− litters as evidenced by the weight loss (Figure 1B) and appearance of soft stool, but a significant difference in weight loss between WT and LPA2−/− mice was observed. Similarly, the clinical score, which quantifies the appearance of occult blood and diarrhea, was significantly lower in LPA2−/− than WT littermates (Supplementary Figure 1A).

Weight loss in LPA2−/− mice was similar to that in WT. Moreover, 3 each of WT and LPA2+/− mice died by day 56 as compared to none among LPA2−/− mice (Figure 2C). WT and LPA2+/− mice developed multiple polypoid tumors in the middle to distal colon, whereas tumors were fewer and smaller in LPA2−/− mice (Figure 2D). The colons of WT and LPA2+/− mice were heavier than that of LPA2−/− mice, indicating occurrence of edema in these mice (Supplementary Figure 1B). There was no difference in macroscopic or microscopic features among untreated mice.

The mean number of tumors in the colon of LPA2−/− mice was 0.7±0.2 at day 36 vs. 1.5±0.6 for WT and 1.8±0.5 for LPA2+/− (Figure 3A) (n = 8, P < 0.05). At day 56, an average of 13.8 ±1.8 and 13.1±1.1 adenomas per animal was found in WT and LPA2+/− mice, respectively (n = 10, P < 0.01). In contrast, LPA2−/− mice developed 6.4±1.3 lesions per animal (Figure 3B). Furthermore, the numbers of tumors larger than 2 mm were significantly less in LPA2−/− mice than in WT or LPA2+/− mice (Figure 3C; 2.8±0.7 for LPA2−/− vs. 6.8 ±0.8 for WT and 7.3 ± 0.5 for LPA2+/− mice). Histological examination of colonic sections showed no notable difference between untreated WT and LPA2−/− littermates (Figure 3D). By day 36, tubular adenomas were present in WT and LPA2+/− mice, but the numbers and size of lesions were comparatively smaller in LPA2−/− mice. At day 56, the numbers and size of lesions were progressively increased in all mice, but the polyps were flatter and smaller in LPA2−/− mice compared to those in WT or LPA2+/− mice. Together these results show that the absence of LPA2 protected animals from the combination treatment of AOM and DSS and suggest a crucial role of LPA2 in the progression of tumor in the colon. Heterozygosity of LPA2, however, was not sufficient for the protection and we will not display data from LPA2+/− mice hereafter.

**Decreased Cell Proliferation in LPAβ−/− mice**

The difference in tumor size between WT and LPA2−/− mice suggests that there may be an underlying difference in the rate of cell proliferation. Epithelial cell proliferation was examined by immunohistological staining of Ki67. In untreated mice, Ki67 labeling was confined to the nuclei of epithelial cells located at the base of colonic crypts in WT and LPA2−/− mice and no observable difference was noted between WT and LPA2−/− mice (Figure 4A and D). Following AOM/DSS treatment, WT mice had a large population of proliferating cells in non-tumorous crypts as well as in tumors (Figure 4B and C). Ki67 labeling extended from the base of the crypt to more than half way of the crypt height and elongation of the crypt height compared to untreated animals was evident (Figure 4B). On the contrary, Ki67-positive epithelial cells were largely limited to the base region of the crypt in LPA2−/− mice (Figure 4E and F), suggesting that LPA2 is involved in proliferation of epithelial cells in the crypts following AOM and DSS treatment.

**β-catenin and KLF5 expression in LPAβ−/− mice**

Previous studies have linked the proliferation of CC cells by LPA to the regulation of β-catenin and KLF5 19, 20. To determine whether differential expression of β-catenin contributes to the
cell proliferation, we examined β-catenin expression in WT and LPA<sup>−/−</sup> mice. Figure 5A shows immunohistological staining of β-catenin in epithelial cells of colonic section. In treated WT mice, β-catenin labeling was more evident in the cytoplasm and nuclei of epithelial cells in adenomas (Figure 5B–c and b vs. a). In comparison, up-regulation of β-catenin in LPA<sup>−/−</sup> mice was substantially lower and less nuclear staining was observed, demonstrating that LPA<sub>2</sub> regulates activation of β-catenin <sup>in vivo</sup>.<sup>19, 20</sup>

Figure 5B shows that KLF5 protein expression was significantly up-regulated in treated WT mice. Immunohistological staining of KLF5 shows that all epithelial cells in the crypts of WT and LPA<sup>−/−</sup> mice were positive for KLF5 expression (Figure 5C-a and d). In treated WT mice (Figure 5C-b), the staining of KLF5 was more intense in the base of the crypt and KLF5 labeling extended to the epithelial cells near the surface. In comparison, a small increase in KLF5 expression was observed in AOM/DSS-treated LPA<sup>−/−</sup> mice (Figure 5B) and the neck of the colon crypts were less populated with KLF5-positive cells in these mice relative to WT mice (Figure 5C–e and f). Together, these results suggest that the differential expression of β-catenin and KLF5 might provide the molecular basis for the decreased cell proliferation in AOM and DSS treated LPA<sup>−/−</sup> mice.

Reduced COX-2 expression in LPA<sup>−/−</sup> mice

An increase in COX-2, which generates prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) from arachidonic acid, has been associated with the progress of CC<sup>24</sup>. Hence, we examined the expression of COX-2 proteins by Western blot and immunohistochemical analysis. The expression level of COX-2 protein was slightly lower in untreated LPA<sup>−/−</sup> mice than untreated WT mice (Figure 5D). This difference can also be seen in immunohistochemical staining (Figure 5E, a vs. d). AOM/DSS treatment resulted in a significant increase in COX-2 protein expression in WT mice. Epithelial expression of COX-2 in colon crypt of WT mice was observed (Figure 5E-b), but COX-2 expression was largely found in lamina propria cells (Figure 5E-c). Induction COX-2 expression in LPA<sup>−/−</sup> mice was markedly lower compared with WT mice (Figure 5D, 5E-e and f) and clearly fewer COX-2 expressing lamina propria cells were found in LPA<sup>−/−</sup> mice.

Cytokine induction in LPA<sup>−/−</sup> mice

Previous studies have shown that LPA can induce secretion of cytokines and chemokines from cancer cells, including CC<sup>10, 25, 26</sup>. We contemplated whether there was a difference in the expression of cytokines and chemokines between WT and LPA<sup>−/−</sup> mice. The expression levels of various cytokines and chemokines were determined by qRT-PCR and the results are shown in Figure 6A. There was no apparent difference in TNF-α, INF-γ, IL-1β, and IL-6 expression in untreated WT and LPA<sup>−/−</sup> mice, and AOM and DSS markedly stimulated expression of these cytokines in both mice. Although the expression levels of TNF-α, INF-γ, IL-1β, and IL-6 in treated LPA<sup>−/−</sup> mice were lower compared to WT mice, they did not reach statistical significance. In contrast, we observed a significant difference in the expression of MCP-1 and MIF between WT and LPA<sup>−/−</sup> mice. Whereas the expression levels of MCP-1 and MIF were elevated more than 3-fold in treated WT mice, small increases were observed in LPA<sup>−/−</sup> mice. Moreover, the basal expression levels of MCP-1 and MIF were lower in LPA<sup>−/−</sup> than WT mice. The induction of MCP-1 and MIF was confirmed <sup>in vitro</sup> by treating Caco-2 cells with LPA (Supplemental Figure 2). Together, these results suggest LPA<sub>2</sub>-mediated signaling specifically regulates the expression of pro-inflammatory factors such as MCP-1 and MIF.

Infiltration of inflammatory cells

Early during tumor formation, stromal cells and tumor-infiltrating leukocytes provide signals that regulate cancer cell growth and differentiation. Because MCP-1 mRNA level was markedly decreased in LPA<sup>−/−</sup> mice, we next determined whether the lack of LPA<sub>2</sub> affected
infiltration of inflammatory cells. Histological analysis showed massive infiltration of neutrophils in AOM/DSS-treated mice and quantification of neutrophil infiltration is shown in Figure 6C. Marked increases in MPO activity were observed in WT and LPA2−/− mice, but with no difference between the two groups, implying that infiltration of neutrophils was not affected by the absence of LPA2. On the contrary, immunohistochemical analysis using an anti-Mac-3 antibody showed extensive infiltration of macrophages in WT mice, whereas a reduction in the number of macrophages in the lamina propria of LPA2−/− mice was evident. These results show that a decrease in macrophage infiltration is a part of the protective mechanisms rendered by the absence of LPA2.

**AOM-induced neoplasia**

The combination treatment of AOM and DSS relies on inflammatory response evoked by DSS intake, which hasten the development of adenocarcinomatous lesions 16. To determine whether enhanced inflammatory response is needed to observe the protective effect of loss of LPA2 function, we subjected WT and LPA2−/− mice with AOM alone. WT and LPA2−/− mice both developed ACF, but significantly smaller numbers of ACF were found in the colons of LPA2−/− mice than in WT control mice (Figure 7). The mean number of ACF in WT mice was 24.3 ± 2.1 vs. 11.6 ± 1.5 for LPA2−/− mice (n = 9, P < 0.01). No ACF was found in salinetreated WT or LPA2−/− mice (data not shown). These results show that the loss of LPA2 function impeded the formation of early neoplastic lesions in the colon without onset of inflammation.

**DISCUSSION**

The prominent production of LPA and the effects of LPA in most ovarian and prostate cancer cells along with over-expression of LPA2 have suggested the autocrine system of LPA-LPA2 axis promotes growth and invasion of such cancers 3, 6, 7. More recently, over-expression of LPA2 in colon cancer patients has been shown and suggests a potential role of LPA2 in colon cancer 9, 10. However, the absence of tumor in ovaries of LPA2 transgenic mice has left the role of LPA2 in tumorigenesis uncertain 14. In this study, we determined the importance of LPA2 in CC by characterizing the loss of LPA2 function in mice. By challenging LPA2−/− mice with agents that induce dysplasia in the colon, we were able to reveal the pathological importance of LPA2 in CC. Our data herein demonstrate that the absence of LPA2 results in a marked decrease in tumor incidence and progression of colon adenocarcinomas. The amelioration of CC in LPA2−/− mice was accompanied by a decrease in both cell proliferation and chemokine expression, providing insights into the protection against CC in LPA2−/− mice. Although our study was focused on the characterization of a CAC model, the propensity to protect animals was consistent in the study using AOM alone. To our knowledge, the current study is the first direct evidence demonstrating the importance of LPA2 in colon carcinogenesis in vivo and our data suggest LPA2 as a potential target for preventive strategies for CC.

The absence of tumors in the transgenic LPA2 ovaries suggests incomplete capacity of the LPA-LPA2 signaling axis to initiate cancer and it has been suggested that LPA2 might increase the susceptibility to develop cancer or hasten cancer progress when other genetic factors are present 14. This is in part supported by our current study in which LPA increased the number and size of adenomas in ApcMin/+ mice that are predisposed to forming adenomas in the small intestine 27. However, our study does not specifically address whether the increase in adenomas in Apcmin/+ mice by LPA resulted from signaling by LPA2 despite upregulation of LPA2 expression in these mice. A further study based on deletion of LPA2 in ApcMin/+ background is needed to fully recapitulate this aspect.

The Wnt/β-catenin cascade plays a single most dominant role in controlling cell fate along the crypt-villus axis. Once the Wnt/β-cascade is mutationally activated, the adenoma cells maintain
their progenitor status populating entire villi. LPA had been shown to inactivate glycogen synthase kinase-3 in NIH3T3 and HEK293 cells although nuclear accumulation of β-catenin by LPA was not reported in these cells. On the other hand, Yang et al. have shown that LPA activates the β-catenin pathway in HCT116 and LS174T human CC cells, resulting in an accumulation of β-catenin in the nucleus. However, we previously reasoned that LPA might be able to influence proliferation of CC cells independent of the Wnt/β-catenin cascade as the Wnt/β-catenin cascade is often mutated in CC cells. This led us to identify KLF5 as an additional target of LPA-elicited signaling that regulates proliferation of CC cells. KLF5, a member of a family of zinc-finger-containing transcription factors, is predominantly expressed in the crypt compartment of intestine where cells rapidly replicate. Our data show a number of features demonstrating LPA-dependent proliferation of epithelial cells in the crypts. AOM and DSS induced hyperplasia, as evidenced by the expansion of Ki67-positive cells and concurrent up-regulation of β-catenin and KLF5 expression in WT mice. In contrast, the crypt height of LPA2−/− mice was not only shorter but proliferating cells were largely confined to the crypt base along with significantly lower presence of nuclear β-catenin and KLF5. β-catenin and KLF5 are transcriptional factors, which can activate targets such as c-Myc, cyclin D, cyclin B1, and Cdc2. In addition, LPA has previously been shown to induce the generation of reactive oxygen species and subsequent activation of downstream genes. Hence, this ability of LPA to regulate oncogenes and tumor suppressor genes suggests a potential role of LPA as a mutagen.

Whereas our study demonstrates the pro-proliferative effect of LPA2-mediated signaling on intestinal epithelial cells, increased epithelial cell proliferation alone is insufficient to cause cancer. LPA, however, is capable of inducing effects that potentially contribute to cancer progress. Herein we showed that COX-2 induction following AOM and DSS administration was markedly reduced in LPA2−/− mice. The link between COX-2 and CC is supported by a variety of studies. Studies have shown that COX-2 expression is elevated in human CC patients and ApcMin/+ mice and epidemiological studies have demonstrated the efficacy of COX-2 inhibitors in reducing the tumor incidence in CC patients. In AOM and DSS-treated LPA2−/− mice, significantly fewer COX-2 positive cells was detected compared with WT mice. Moreover, the basal COX-2 expression in LPA2−/− mice was lower in untreated LPA2−/− mice than WT, suggesting a role of LPA2 in maintenance of basal COX-2 expression. These findings are consistent with previous studies that LPA is an inducer of COX-2 expression in ovarian cancer cells and that LPA3−/− mice have reduced levels of COX-2 and PGE2/PGI2 that result in a defect in implantation.

LPA is a potent inducer of cytokines and angiogenic factors. LPA2 transgenic mice secreted increased amounts of vascular endothelial growth factor and urokinase-type plasminogen activator. The down-regulation of MCP-1 and MIF in LPA2−/− mice is especially significant as this represents one potential mechanism where the absence of LPA2 ameliorates CC progress. MCP-1 is a chemoattractant for monocytes, endothelial cells, and a subset of T lymphocytes, and its expression correlates with macrophage infiltration and tumor vessel density in human colorectal cancer. The reduced MCP-1 expression is in part thought to be responsible for the decrease in the number of infiltrating macrophages in LPA2−/− mice. Macrophages are one of the predominant stromal cells that are found in cancers and studies have correlated the macrophage infiltration and the prognosis of cancers. Macrophages contribute to tumor progression by producing matrix metalloproteinases as well as COX-2 and PGE2. Previously, F4/80-positive macrophages and to a lesser extent neutrophils were shown to be the major COX-2 producing leukocytes in the colon of AOM and DSS treated mice. Hence, our finding of reduced MCP-1 expression in LPA2−/− mice parallels the decreased infiltration of macrophages and COX-2 expression. Our in vitro study showed that LPA can stimulate MCP-1 secretion from human CC cells and, hence, we suggest that LPA-LPA2 signaling axis is a major contributor of MCP-1 in the intestine and that under the...
pathological conditions, such as cancer, MCP-1 secreted by the epithelial cells induces transepithelial migration of macrophages, which adds to tumor progression.

Another effect observed in LPA$_2^{-/-}$ mice was the induction of MIF. Over-expression of MIF has been shown in several neoplasms, including prostate and colorectal cancer. $^{40, 41}$ In addition, increased expression of MIF in human and Apc$^{min/+}$ mouse adenomas has been reported and homozygous deletion of mif gene in Apc$^{min/+-}$ mice decreased the number and size of adenomas, providing direct evidence for its function in colon carcinogenesis. $^{42}$ Multiple effects have been ascribed to MIF, including tumor invasion, angiogenesis, and down-regulation of the tumor suppressor p53, suggesting that increased expression of MIF might exacerbate tumor progression by suppressing p53-mediated growth arrest and apoptosis. $^{42–44}$ MIF is abundantly expressed in intestinal epithelial cells, but during inflammatory processes as well as cancer, macrophages are thought to be a major producer of MIF. $^{45}$ The mechanisms underlying the up-regulation of MIF expression during the early stage of intestinal tumorigenesis is unclear, but our data suggest that the LPA-LPA$_2$ signaling axis is a significant contributor to this regulation.

In summary, we demonstrated that the loss of LPA$_2$ significantly attenuated the progression of CC. During the recent years, several inhibitors targeting LPA receptors have been synthesized $^{46–48}$, but these inhibitors target LPA$_1$ or LPA$_3$, but not LPA$_2$. Recently, LPA$_2$-specific compound was reported, but this compound was not available to examine the efficacy of LPA$_2$-specific inhibition as a therapeutic strategy for CC prevention. However, our current study show that inhibiting LPA$_2$-mediated signaling has potential to restrict tumor progression and targeting LPA$_2$ might be a new strategy for CC prevention and treatment.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors are grateful to Dr. Asma Nusrat for valuable comments and Dr. Mauricio Rojas for the use of a microtome.

Funding sources: This work was supported by grants from the National Institutes of Health (DK071597 (C.C.Y.), DK052230 (V.W.Y.), MH51699, HD050685, and NS048478 (J.C.), S.L. is supported by a Research Fellowship Award from the Crohn’s and Colitis Foundation of America. We acknowledge the Emory Digestive Disease Research Development Center (supported by DK064399) for the use of light microscope.

Abbreviations

LPA  
lysophosphatidic acid

AOM  
a zxomethane

DSS  
dextran sulfate sodium

CAC  
colitis-associated cancer

Apc  
ad enomatous polyposis coli

ACF
aberrant crypt foci

**COX-2**
cyclooxygenase-2

**PG**
prostaglandin

**MCP-1**
monocyte chemoattractant protein 1

**MIF**
Macrophage migration inhibitory factor

**References**


*Gastroenterology.* Author manuscript; available in PMC 2010 May 1.


Figure 1.
The effect of LPA on tumor incidence in Apc\textsuperscript{Min/+} mice
(A) The expression of LPA receptors in adenomas of Apc\textsuperscript{Min/+} mice was determined by quantitative RT-PCR. W: WT, M: Apc\textsuperscript{Min/+}. n = 6. *, \( P < 0.05 \). **, \( P < 0.01 \). (B) The effect of LPA on colonic tumorigenesis was determined by oral administration of LPA to Apc\textsuperscript{Min/+} mice. Six weeks old male C57BL/6 and Apc\textsuperscript{Min/+} mice were given 10 \( \mu \)g/kg LPA suspended in 0.1% BSA containing PBS by gavage once every three days for one month. Control animals received the same volume of PBS+BSA. Animals were killed one month after the last LPA administration and the small intestine was examined under a dissecting microscope for the presence of adenomas. Each data point represents the number of adenomas found in the entire intestine of each mouse. Horizontal bars show the median of each group. n = 9. **, \( P < 0.001 \).
Figure 2.
Tumor formation induced by AOM and DSS treatment
(A) Schematic presentation of AOM and DSS treatment (B) Body weight changes represented as mean ± SE during the course of AOM and DSS treatment. *, $P < 0.05$ compared with WT. (C) Mortality were followed during the course of AOM and DSS treatment. (D) Representative gross appearance of colon of WT, LPA$_2$$^{+/−}$, and LPA$_2$$^{−/−}$ littermates.
Figure 3.
Reduced tumors in LPA2−/− mice
Numbers of tumors at (A) day 36 or (B) day 56 in the colons of WT, LPA2+/−, and LPA2−/− mice were counted under the microscope. Each point represents the number of tumors in the colon of each mouse. Horizontal bars represent the mean. n ≥ 8. *, P < 0.01. (C) The number of tumors larger than 2 mm in diameter at day 56 is shown. Each value represents the mean ± SE. n=10. *, P < 0.01. (D) Representative colon tissues stained with H&E. n = 6. Magnification: x100.
Figure 4.
Reduced cell proliferation in LPA$_2^{-/-}$ mice
Paraffin embedded colonic sections from untreated (A and D) and AOM and DSS treated WT (B-C) and LPA$_2^{-/-}$ (E-F) mice were deparaffinized and immunolabeled using an antibody against Ki67. n = 5. Magnification at x100.
Figure 5.
Expression of β-catenin, KLF5, and COX-2

(A) Colon tissues of untreated and AOM and DSS-treated WT and LPA$_2^{-/-}$ mice were stained with antibodies against β-catenin. WT: a–c; LPA$_2^{-/-}$: d–f. n=5. Magnification: a and d at x630; b–c and e–f at x100 (B) Western blot shows KLF5 protein expression in the colon of WT and LPA$_2^{-/-}$ mice, n = 3. (C) Representative immunohistologic staining of colonic tissues for KLF5 are shown (n = 5). WT: a–c; LPA$_2^{-/-}$: e–f. Magnification: a–b and d–e at x100; c and f at x400. (D) COX-2 protein expression in protein extracts from the colons of WT and LPA$_2^{-/-}$ mice was determined by Western immunoblotting. n = 3. (B) Immunohistological analysis of COX-2 expression in colon tissues from WT and LPA$_2^{-/-}$ mice. n = 5. Magnification: x400.
Figure 6.
Cytokine gene expression in the colon
(A) Quantitative RT-PCR was performed on total RNAs from the colons of WT and LPA2−/− mice before and after treatment with AOM and DSS. Data are presented as mean ± SE from at least 6 mice from each group. *, P < 0.05; #, P <0.001 compared to untreated WT. +, P < 0.05 compared to untreated LPA2−/−. (C) MPO activity was measured in the colons of WT and LPA2−/− mice. n ≥ 8 mice from each group. (D) immunohistological analysis of Mac-3-positive macrophage in colon tissues from WT and LPA2−/− mice. n = 5.
Figure 7.
ACF formation by AOM treatment
WT and LPA$_2^{-/-}$ mice were given repeated intraperitoneal injection of AOM. The number of ACF was determined in methylene blue stained colons. Each data point represents the number of ACF in each mouse. n = 9 per group. *, $P < 0.001$. 